Funder
Eli Lilly Japan
Mitsubishi Tanabe Pharma Corporation
Eli Lilly and Company
Publisher
Springer Science and Business Media LLC
Reference31 articles.
1. Fauzi M, Kartiko-Sari I, Poudyal H. Trends of dietary intakes and metabolic diseases in Japanese adults: assessment of National Health Promotion Policy and National Health and Nutrition Survey 1995–2019. J Clin Med. 2022;11:2350.
2. Kohsaka S, Morita N, Okami S, Kidani Y, Yajima T. Current trends in diabetes mellitus database research in Japan. Diabetes Obes Metab. 2021;23(Suppl 2):3–18.
3. Examination Committee of Criteria for “Obesity Disease” in Japan; Japan Society for the Study of Obesity. New criteria for “obesity disease” in Japan. Circ J. 2002;2002(66):987–92.
4. Muramoto A, Matsushita M, Kato A, et al. Three percent weight reduction is the minimum requirement to improve health hazards in obese and overweight people in Japan. Obes Res Clin Pract. 2014;8:e466–75.
5. Okauchi Y, Nishizawa H, Funahashi T, et al. Reduction of visceral fat is associated with decrease in the number of metabolic risk factors in Japanese men. Diabetes Care. 2007;30:2392–4.